EUROSETS
3.2.2021 09:32:12 CET | Business Wire | Press release
Eurosets , a leader in the development, production and commercialization of advanced medical devices, announces the full commercial release of its novel ECMOlife system for ExtraCorporeal Life Support (ECLS) . This release comes after a successful pre-market clinical evaluation in which critically ill patients were supported by the device for a cumulative period of over 400 days with the longest individual treatment lasting 27 days.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210203005034/en/
ECMOlife expands Eurosets' portfolio to provide temporary support to patients in different therapeutic areas, including ExtraCorporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS). These therapies are used to treat patients suffering from ventricular disease, cardiac arrest or respiratory failure resulting from acute respiratory distress syndrome (ARDS), H1N1, SARS, or COVID-19 infections .
ECMOLife is a life-saving device that is able to temporarily replace the functions of severely compromised heart and lungs. The device acts as an external artificial organ connected to the patient through the main blood vessels and is used in cases where pharmacological therapy is considered insufficient.
Featuring a magnetic-levitating centrifugal pump, optimal performance and enhanced biocompatibility, ECMOlife is the most gentle, safe and versatile solution for ECLS . It is also the only device available on the market with an integrated backup system, ensuring greater patient safety and easier management for healthcare professionals even during extra-hospital transports .
ECMOlife underwent a pre-market evaluation across nine centers in Europe. The device was adopted for treatment of critically ill Covid-19 patients when mechanical ventilation was unsuccessful, as well as patients suffering from post-cardiotomy cardiogenic shock, undergoing lung transplant or requiring cardiopulmonary assistance.
One of the first centers to use ECMOlife was the University Hospital of Brussels . The ECLS team, led by Prof. Dr. Meir , Head of Cardiac Surgery, Prof. Dr. De Waele , Head of the ICU and Dr. Kurt Staessens , Head of the Cardiovascular Perfusion Group, reported about their experience: “We are really pleased with the performance of ECMOLife. The magnetic levitation technology can reduce the level of hemolysis and the risk of thrombus generation. In addition, the non-invasive monitoring system combined with the unique integrated backup unit may improve patient care, ensuring additional safety in the event of an emergency".
"Our mission is to offer new solutions to patients who do not benefit from traditional therapies and ECMOLife is fully in line with these core beliefs”, said Antonio Petralia, Executive Vice President & CEO of Eurosets . "Our device supported critically ill patients for 6 months since its pre-market clinical evaluation release in Europe and we are now very proud to have it fully available to help patients and clinicians worldwide."
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005034/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 21:44:00 CEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
TOURISE and Oxford Economics Release New Global Report on Tourism Resilience in an Era of Permanent Disruption17.8.2026 16:33:00 CEST | Press release
New analysis shows destinations that assume risk will recover up to 1.5 times faster with global rehabilitation times dropping from 24 months to as little as 10 TOURISE, in collaboration with Oxford Economics, today released a new report, “Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption.” The analysis of 85 major crises over two decades shows a clear pattern: in a world defined by continuous shocks, destinations that act before disruption hits recover up to 1.5 times faster than those that wait. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817880835/en/ “In a world that does not reset between crises, disruption is a constant feature of the global tourism landscape,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. “The real test for destinations measures how they prepare for volatility, protect traveler confidence, and mai
The Expensify Visa® Commercial Card Brings New Proactive Spend Controls to 14 Countries17.8.2026 15:00:00 CEST | Press release
New admin-defined spend rules let businesses control how, where, and when every card is used, stopping the wrong spend before it happens instead of cleaning it up after. Expensify, Inc. (Nasdaq: EXFY), the easiest way to manage expenses, travel, and corporate cards, today expanded the reach of Expensify Card spend rules, the market-leading way for businesses to control corporate card spend before it happens. Available to businesses in 14 countries, spend rules let admins decide exactly how, where, and when each Expensify Card can be used, so only compliant transactions go through. Unlike traditional corporate cards that rely on after-the-fact expense review, the Expensify Card enforces policy at the point of purchase. Admins set the rules once, and the card handles the rest. With Expensify Card spend rules, admins can: Lock a card to a subscription. Give each recurring SaaS tool its own virtual card, so a vendor can only ever charge what it should. If the card owner changes teams or le
Riskified Analysis Finds Travel Fraudsters Are Adapting Faster Than Traditional Signals Can Keep Up, With May Flight Risk Up 32%17.8.2026 14:30:00 CEST | Press release
New Travel Industry report reveals sophisticated fraud rings are exploiting trusted customer behaviors across flights, hotels, and travel platforms Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released new findings from its Travel Industry Insights report, revealing how sophisticated fraud rings and AI-enabled fraudsters are evolving their tactics across airlines, hotels, and online travel platforms. Riskified’s analysis shows that fraudsters are increasingly adapting their behavior to resemble legitimate travelers, making traditional fraud indicators less reliable and creating new challenges for travel merchants. Riskified’s analysis of hundreds of millions of travel transactions across flights, hotels, and land transportation found that flight fraud risk increased through the first five months of 2026, with May 2026 marking the sharpest year-over-year increase at 32% compared to May 2025. The findings show that sophisticated fraud activity i
PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 13:54:00 CEST | Press release
Revenue rose 9% to $120 billion while net profit more than doubled to $17 billionCumulative domestic investments reached more than $199 billion since 2021PIF has contributed more than $342 billion to Saudi Arabia’s real non-oil GDP between 2021 and 2025Assets under management exceed $900 billion, up from around $530 in 2021 and $150 billion in 2015 PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom